| abstract |
Disclosed is an oxazolidinone derivative of general formula (I), wherein R is a group of general formula (a), wherein n means 1 or 2, R1 H, R2 OH, OA, Oar, Ohet, NHOH, NH2, NHA or NA2, R3 A- CO, ArCO, Het-CO, Het-O-CO, Ar-O-CO, A-O-CO-, Ar-SO2 or A-SO2, A C1-6 alkyl, Ar C6-10 aryl, diphenylmethyl, or benzyl, which are o ptionally substituted by 1, 2 or 3 substituents from the complex A, F, Cl, Br, J, AO, -O-CH2-O, COOA, COOH, CF3, OH, NO2, CN, -O-C O-A, NH2, NHA and NA2, Het mono or bicyclic, saturated, unsaturat ed or aromatic heterocyclic group with 1 to 4 N, O and/ or S, opt ionally substituted by one substituent from the complex F, Cl, Br , CF3, A, OH, OA, CN and NO2, and its physiologically suitable sa lts prevent binding of fibrinogen to the related receptors and ar e suitable for treatment of thrombosis, osteoporosis, tumorous di seases, apoplexy, heart attack, ischemias, inflammations, arterio sclerosis and osteolytic diseases. |